en associated with convulsions. ( 5.3 ) pseudotumor cerebri (idiopathic intracranial hypertension): have been reported in pediatric patients receiving gnrh agonists, including leuprolide acetate. monitor patients for headache, papilledema, and blurred vision. ( 5.4 ) 5.1 initial rise of gonadotropins and sex steroid levels during the early phase of therapy, gonadotropins and sex steroids rise above baseline because of the initial stimulatory effect of the drug [see clinical pharmacology ( 12.2 )] . therefore, an increase in clinical signs and symptoms of puberty including vaginal bleeding may be observed during the first weeks of therapy or after subsequent doses [see adverse reactions (6) ] . instruct patients and caregivers to notify the physician if these symptoms continue beyond the second month after fensolvi administration. 5.2 psychiatric events psychiatric events have been reported in patients taking gnrh agonists, including leuprolide acetate. postmarketing reports with this class of drugs include symptoms of emotional lability, such as crying, irritability, impatience, anger, and aggression. monitor for development or worsening of psychiatric symptoms during treatment with fensolvi [see adverse reactions (6.1 , 6.2) ] . 5.3 convulsions postmarketing reports of convulsions have been observed in patients receiving gnrh agonists, including leuprolide acetate. these included patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and patients on concomitant medications that have been associated with convulsions such as bupropion and ssris. convulsions have also been reported in patients in the absence of any of the conditions mentioned above [see adverse reactions (6.2) ] . 5.4 pseudotumor cerebri (idiopathic intracranial hypertension) pseudotumor cerebri (idiopathic intracranial hypertension) have been reported in pediatric patients receiving gnrh agonists, including leuprolide acetate. monitor patients for signs and symptoms of pseudotumor cerebri, including headache, papilledema, blurred vision, diplopia, loss of vision, pain behind the eye or pain with eye movement, tinnitus, dizziness, and nausea.

to fensolvi with a gnrh agonist stimulation test, basal serum luteinizing hormone (lh) levels or serum concentration of sex steroid levels at 1 to 2 months following initiation of therapy and as needed to confirm adequate suppression of pituitary gonadotropins, sex steroids, and progression of secondary sexual characteristics. measure height (for calculation of growth velocity) every 3 to 6 months and monitor bone age periodically. noncompliance with drug regimen or inadequate dosing may lead to gonadotropins and/or sex steroids increasing above prepubertal levels resulting in inadequate control of the pubertal process. if the dose of fensolvi is not adequate, switching to an alternative gnrh agonist for the treatment of cpp with the ability for dose adjustment may be necessary. 2.3 reconstitution instructions use aseptic technique including gloves for reconstitution and administration. allow the product to reach room temperature before reconstitution to allow for easier administration. once reconstituted, the concentration is 45 mg/0.375 ml. administer the product within 30 minutes or discard. fensolvi is packaged in a carton containing two trays and this package insert: table 1: contents of the two trays in the fensolvi carton syringe a tray syringe b tray syringe a is prefilled with diluent for reconstitution (atrigel delivery system) syringe b is prefilled with 45 mg lyophilized leuprolide acetate powder white plunger rod (to be used with syringe b) safety needle (18g x 5/8") desiccant pack desiccant pack follow the instructions below to prepare fensolvi: 1. on a clean field, open both trays by tearing off the foil from the corners and removing the contents. discard the desiccant pack(s). open the safety needle package by peeling back the paper tab. 2. pull out (do not unscrew) the short blue plunger rod with attached gray stopper from syringe b and discard. 3. gently screw the white plunger rod into the remaining gray stopper in syringe b. 4. unscrew and discard the clear cap from syringe a. 5. remove and discard the gray rubber cap from syringe b. 6. join the two syringes together by pushing and gently screwing until secure. 7. inject the liquid contents of syringe a into the leuprolide acetate powder contained in syringe b. thoroughly mix the product for approximately 45 seconds by pushing the contents back and forth between both syringes to obtain a uniform suspension. when thoroughly mixed, the suspension will appear pale yellow. note: product must be mixed as described; shaking will not provide adequate mixing. 8. after mixing, hold the syringes vertically (upright) with syringe b (wide syringe) on the bottom. the syringes should remain securely coupled. draw all of the mixed product into syringe b by depressing the syringe a plunger and slightly withdrawing the syringe b plunger. 9. unscrew syringe a to decouple the syringes while continuing to withdraw the syringe b plunger. note: small air bubbles will remain in the formulation – this is acceptable. 10. continue to hold syringe b upright with the open end at the top. hold back the white plunger on syringe b to prevent loss of the product and attach the safety needle cartridge. gently screw clockwise with approximately a three-quarter turn until the needle is secure. do not overtighten, as the hub may become damaged resulting in leakage of the product during injection. the safety sheath may also be damaged if the needle is screwed with too much force. 11. (1) move the safety sheath away from the needle and towards the syringe and (2) pull off the clear needle cartridge cover immediately prior to administration. note: should the needle hub appear to be damaged, or leak, do not use the product. if the needle hub is damaged or leakage is observed, use a new fensolvi carton. figure 1 figure 2 figure 3 figure 4 figure 5 figure 6 figure 7 figure 8 figure 9 figure 10 step10 figure 12 2.4 administration instructions 1. select a subcutaneous injection site on the abdomen, upper buttocks, or another location with adequate amounts of subcutaneous tissue that does not have excessive pigment, nodules, lesions, or hair. avoid areas with brawny or fibrous subcutaneous tissue or locations that could be rubbed or compressed (i.e., by a belt or clothing waistband). rotate injection sites with each injection. 2. cleanse the injection-site area with an alcohol swab (not enclosed). 3. using the thumb and forefinger, grab and bunch the area of skin around the injection site. 4. using your dominant hand, insert the needle quickly at a 90° angle to the skin surface. the depth of penetration will depend on the amount and fullness of the subcutaneous tissue and the length of the needle. after the needle is inserted, release the skin. 5. inject the drug using a slow, steady push and press down on the plunger until the syringe is empty. 6. withdraw the needle quickly at the same 90° angle used for insertion. 7. immediately following the withdrawal of the needle, activate the safety shield using a finger/thumb or flat surface and push until it completely covers the needle tip and locks into place. 8. an audible and tactile “click” verifies a locked position. 9. check to confirm the safety sheath is fully engaged. discard all components safely in an appropriate biohazard container. fig1 fig2 figure 2-4-3 figure 7 figure 2-4-5 figure 2-4-6

l trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. fensolvi was evaluated in an uncontrolled, open-label, single-arm clinical trial in which 64 pediatric patients with cpp received at least one dose of fensolvi. the age ranged from 4 to 9 years at start of treatment; 62 patients were female and 2 were male; 53% white; 23% black; 8% american indian or alaska native; 5% asian; 2% native hawaiian or other pacific islander. 56% of the subjects self-identified as hispanic or latino ethnicity. adverse reactions that occurred in ≥ 5% of patients are shown in table 2. table 2: adverse reactions occurring in ≥ 5% of patients treated with fensolvi in an open-label, single-arm trial adverse reactions % of patients (n=64) injection site pain 31 nasopharyngitis 22 pyrexia 17 headache 16 cough 13 abdominal pain 9 injection site erythema 9 nausea 8 constipation 6 vomiting 6 upper respiratory tract infection 6 bronchospasm 6 productive cough 6 hot flush 5 other adverse reactions: psychiatric emotional disorder (2%) and irritability (2%) 6.2 postmarketing experience the following adverse reactions have been identifed during postapproval use of leuprolide acetate or fensolvi. because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. allergic reactions: anaphylactic, rash, urticaria, and photosensitivity reactions. general : chest pain, weight increase, weight decrease, decreased appetite, fatigue. laboratory abnormalities: decreased wbc. metabolic : diabetes mellitus. musculoskeletal and connective tissue : arthralgia, epiphysiolysis, muscle spasms, myalgia. neurologic: neuropathy peripheral, convulsion, paralysis, insomnia, pseudotumor cerebri (idiopathic intracranial hypertension). psychiatric: emotional lability, such as crying, irritability, impatience, anger and aggression. depression, including rare reports of suicidal ideation and attempt. many, but not all, of these patients had a history of psychiatric illness or other comorbidities with an increased risk of depression. skin and subcutaneous tissue : injection site reactions including induration and abscess, flushing, hyperhidrosis. reproductive system: vaginal bleeding, breast enlargement. vascular : hypertension, hypotension. respiratory: dyspnea.

mended human dose based on body surface area using an estimated daily dose. a similar rat study also showed increased fetal mortality and decreased fetal weights but no major fetal abnormalities at doses less than the recommended human dose based on body surface area using an estimated daily dose (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data when administered on day 6 of pregnancy at test dosages of 0.00024 mg/kg, 0.0024 mg/kg, and 0.024 mg/kg (1/3255 to 1/33 of the human dose) to rabbits, leuprolide acetate produced a dose-related increase in major fetal abnormalities. similar studies in rats failed to demonstrate an increase in fetal malformations. there was increased fetal mortality and decreased fetal weights with the two higher doses of leuprolide acetate in rabbits and with the highest dose (0.024 mg/kg) in rats. 8.2 lactation risk summary there are no data on the presence of leuprolide acetate in either animal or human milk, the effects on the breastfed infants, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for fensolvi and any potential adverse effects on the breastfed infant from fensolvi or from the underlying maternal condition. 8.3 females and males of reproductive potential pregnancy testing exclude pregnancy in women of reproductive potential prior to initiating fensolvi if clinically indicated [see use in specific populations ( 8.1 ) ] . contraception females fensolvi may cause embryo-fetal harm when administered during pregnancy. fensolvi is not a contraceptive. if contraception is indicated, advise females of reproductive potential to use a non-hormonal method of contraception during treatment with fensolvi [see use in specific populations ( 8.1 )] . infertility based on its pharmacodynamic effects of decreasing secretion of gonadal steroids, fertility is expected to be decreased while on treatment with fensolvi. clinical and pharmacologic studies in adults (>18 years) with leuprolide acetate and similar analogs have shown reversibility of fertility suppression when the drug is discontinued after continuous administration for periods of up to 24 weeks [see clinical pharmacology ( 12.1 )] . there is no evidence that pregnancy rates are affected following discontinuation of fensolvi. animal studies (prepubertal and adult rats and monkeys) with leuprolide acetate and other gnrh analogs have shown functional recovery of fertility suppression. 8.4 pediatric use the safety and effectiveness of fensolvi for the treatment of cpp has been established in pediatric patients 2 years of age and older. use of fensolvi for this indication is supported by evidence from an adequate and uncontrolled open-label, single-arm study of 64 pediatric patients with cpp with an age range of 4 to 9 years [see clinical studies ( 14 )] . the safety and effectiveness of fensolvi have not been established in pediatric patients less than 2 years old.

y surface area using an estimated daily dose. a similar rat study also showed increased fetal mortality and decreased fetal weights but no major fetal abnormalities at doses less than the recommended human dose based on body surface area using an estimated daily dose (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data when administered on day 6 of pregnancy at test dosages of 0.00024 mg/kg, 0.0024 mg/kg, and 0.024 mg/kg (1/3255 to 1/33 of the human dose) to rabbits, leuprolide acetate produced a dose-related increase in major fetal abnormalities. similar studies in rats failed to demonstrate an increase in fetal malformations. there was increased fetal mortality and decreased fetal weights with the two higher doses of leuprolide acetate in rabbits and with the highest dose (0.024 mg/kg) in rats.

rption after an initial subcutaneous injection of fensolvi 45 mg in pediatric patients 4 to 9 years of age with cpp, leuprolide levels peaked 4 hours postdose with a mean c max of 212.3 ng/ml. absorption occurred in two phases, a burst phase followed by a plateau phase. the mean plateau serum leuprolide level from 4 to 48 weeks was approximately 0.37 ng/ml with a range of 0.18 to 0.63 ng/ml. there was no accumulation of leuprolide after the second dose. distribution the distribution of leuprolide following fensolvi administration was not evaluated in pediatric patients. the mean steady-state volume of distribution of leuprolide following intravenous bolus administration to healthy male volunteers was 27 l. in vitro binding of leuprolide to human plasma proteins ranged from 43% to 49%. elimination metabolism in rats and dogs, administration of 14 c-labeled leuprolide was shown to be metabolized to smaller inactive peptides: a pentapeptide (metabolite i), tripeptides (metabolites ii and iii), and a dipeptide (metabolite iv). these fragments may be further catabolized. in healthy male volunteers, a 1 mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 8.34 l/h, with a terminal elimination half-life of approximately 3 hours based on a two-compartment model. drug metabolism studies were not conducted with fensolvi. upon administration with different leuprolide acetate formulations, the major metabolite of leuprolide acetate is a pentapeptide (m-1) metabolite. excretion drug excretion studies were not conducted with fensolvi. specific populations the pharmacokinetics of fensolvi in hepatically and renally impaired pediatric patients have not been determined.

tides (metabolites ii and iii), and a dipeptide (metabolite iv). these fragments may be further catabolized. in healthy male volunteers, a 1 mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 8.34 l/h, with a terminal elimination half-life of approximately 3 hours based on a two-compartment model. drug metabolism studies were not conducted with fensolvi. upon administration with different leuprolide acetate formulations, the major metabolite of leuprolide acetate is a pentapeptide (m-1) metabolite. excretion drug excretion studies were not conducted with fensolvi. specific populations the pharmacokinetics of fensolvi in hepatically and renally impaired pediatric patients have not been determined.

rformed with leuprolide acetate using bacterial and mammalian systems. these studies provided no evidence of a mutagenic potential.

etate using bacterial and mammalian systems. these studies provided no evidence of a mutagenic potential.

rsed progression of clinical signs of puberty with reductions in growth velocity and bone age. mean growth velocity decreased from 8.9 ± 13.1 cm/yr at 1 month to 6.9 ± 3.1 cm/yr at 6 months and to 6.4 ± 1.9 cm/yr at 12 months. table 4: reproductive hormone levels in pediatric patients with cpp treated with fensolvi 45 mg every 6 months a % (n/n) of patients achieving endpoints endpoint b month 3 month 6 month 9 month 12 lh levels < 4 iu/l 85 (51/60) 87 (54/62) c 85 (50/59) 86 (50/58) estradiol levels < 73.4 pmol/l (< 20 pg/ml) 98 (56/57) 97 (58/60) 98 (56/57) 98 (55/56) testosterone levels < 1 nmol/l (< 28.4 ng/dl) 100 (2/2) 100 (2/2) 100 (2/2) 50 (1/2) fsh levels < 2.5 iu/l 62 (37/60) 66 (41/62) 44 (26/59) 55(32/58) a intent-to-treat population (n=62) b post gnrh agonist stimulation c primary efficacy endpoint eight female patients out of 62 did not meet the primary efficacy criteria for lh <4 iu/l at 6 months. in four of the eight patients, the lh level at 6 months was between 4.2 and 4.8 iu/l. the remaining four patients had lh levels >5 iu/l. however, post stimulation estradiol was suppressed to prepubertal levels (<20 pg/ml) in seven of the eight patients at month 6 and was maintained through month 12.

tment with fensolvi [see warnings and precautions ( 5.2 )] . convulsions inform patients and caregivers that reports of convulsions have been observed in patients receiving gnrh agonists, including leuprolide acetate. patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and patients on concomitant medications that have been associated with convulsions may be at increased risk [see warnings and precautions ( 5.3 )] . pseudotumor cerebri (idiopathic intracranial hypertension) inform patients and caregivers that reports of pseudotumor cerebri (idiopathic intracranial hypertension) have been observed in pediatric patients receiving gnrh agonists, including leuprolide acetate. advise patients and caregivers to monitor for headache, and vision issues such as blurred vision, double vision, loss of vision, pain behind the eye or pain with eye movement, ringing in the ears, dizziness, and nausea. advise patients and caregivers to contact their healthcare provider if the patient develops any these symptoms. [see warnings and precautions ( 5.4 )] . injection site reactions inform patients and caregivers that injection site related adverse reactions may occur such as transient burning/stinging, pain, bruising, and redness. advise patients to contact their healthcare provider if they experience rash or severe injection site reactions [see adverse reactions ( 6.1 )]. pregnancy fensolvi is contraindicated in pregnancy. if the patient becomes pregnant while taking the drug, the patient should be informed of the potential risk to the fetus [see use in specific populations ( 8.1 )]. compliance with the dosing schedule inform caregivers about the importance of adherence to the fensolvi dosing schedule of one injection every 24 weeks [see dosage and administration ( 2.1 , 2.2 )]. rx only revised 04/2022 manufactured by: tolmar, inc. fort collins, co 80526 for tolmar international ltd. dublin 2, ireland d02 t380 distributed by: tolmar pharmaceuticals, inc. fort collins, co 80526 ©2020 tolmar pharmaceuticals, inc. all rights reserved. fensolvi, atrigel, tolmar, and associated logos, are trademarks of the tolmar group. 04006141 rev. 2 04/22